Samarium for osteoblastic bone metastases and osteosarcoma

被引：34
作者：
Anderson, Pete [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 11期
关键词：
153Sm-EDTMP; bone cancer; bone metastases; bone scan; breast cancer; MIMvista fusion imaging software; osteosarcoma; prostate cancer; skeletal neoplasia; radiation therapy; radiopharmaceutical; radiosensitisation; sarnarium-153; lexidronam;
D O I：
10.1517/14656566.7.11.1475
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Samarium-153 lexidronam (Sm-153-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. Sm-153-EDTMP decay has a therapeutic p-emission and ay-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. Sm-153-EDTMP targets multiple sites of disease, with a single administration. Side effects of Sm-153-EDTMP (0.5 - 2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose Sm-153-EDTMP treatment of cancer involving bone.
引用
收藏
页码：1475 / 1486
页数：12
相关论文
共 107 条
  • [51] Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases
    Janjan, NA
    Payne, R
    Gillis, T
    Pololoff, D
    Libshitz, HI
    Lenzi, R
    Theriault, R
    Martin, C
    Yasko, A
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (03) : 171 - 178
  • [52] Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen
    Kennedy, GA
    Durrant, S
    Butler, J
    Morton, J
    Western, R
    Bartlett, ML
    Allison, R
    MacFarlane, DJ
    [J]. LEUKEMIA, 2005, 19 (05) : 879 - 880
  • [53] SM-153 EDTMP AND RE-186-HEDP AS BONE THERAPEUTIC RADIOPHARMACEUTICALS
    KETRING, AR
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1987, 14 (03) : 223 - 232
  • [54] Y-90 TREATMENT OF BONE METASTASES
    KUTZNER, J
    GRIMM, W
    BROD, KH
    ROESLER, A
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1982, 107 (36) : 1360 - 1361
  • [55] A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector:: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma
    Kvinnsland, Y
    Bruland, O
    Moe, L
    Skretting, A
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (02) : 191 - 197
  • [56] 186Re_HEDP for metastatic bone pain in breast cancer patients
    Lam, MGEH
    de Klerk, JMH
    van Rijk, PP
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) : S162 - S170
  • [57] Larsen RH, 2006, IN VIVO, V20, P325
  • [58] LATTIMER JC, 1990, J NUCL MED, V31, P1316
  • [59] LATTIMER JC, 1990, J NUCL MED, V31, P586
  • [60] COMPARISON OF BIOLOGICAL CHARACTERISTICS OF EDTMP COMPLEXES WITH TC-99M, IN-111 AND SM-153 IN RATS
    LAZNICEK, M
    LAZNICKOVA, A
    BUDSKY, F
    PROKOP, J
    KOPICKA, K
    [J]. APPLIED RADIATION AND ISOTOPES, 1994, 45 (09) : 949 - 953
12345678910